Ren-Yuan Bai et al., 2015-04: Medulloblastoma study testing mebendazole across three orthotopic models of different molecular background, including a vismodegib-resistant tumour, with survival and angiogenesis endpoints.
Mice bearing orthotopic PTCH1-mutant medulloblastoma allografts, a group 3 medulloblastoma xenograft, and a PTCH1-mutant medulloblastoma with acquired resistance to the smoothened inhibitor vismodegib were treated with MBZ.
Ren-Yuan Bai et al., 2015-04: Medulloblastoma study testing mebendazole across three orthotopic models of different molecular background, including a vismodegib-resistant tumour, with survival and angiogenesis endpoints. Study type: orthotopic mouse allograft and xenograft medulloblastoma models. N: not stated in the abstract. Country: USA (Johns Hopkins). Dose/route/schedule: not stated in the abstract text captured. Funder: US NIH P30 CA008748, R01 CA157535. Declared conflicts: no COI statement in the record. Comparator: untreated tumour-bearing mice; vismodegib resistance as a model feature. Also filed as MBB-18 (claims C3, C5). Study type: animal.
